What happened
Samsung E&A updated a previously disclosed supply contract with Samsung Biologics, now worth US$1.18B, about 16.67% of its recent annual revenue, running through Apr 2026.
For context, this single contract equals about 16.67% of the company's most recent annual revenue.
| Counterparty | Samsung Biologics |
|---|---|
| Contract value | US$1.18B |
| vs. recent revenue | 16.67% |
| Through | Apr 2026 (from Nov 2022) |
| Filed | 2026-05-22, [Amended] Supply contract signed |
| Source | DART rcept 20260522800689 → open original filing |
Source: DART. Information only, not investment advice.